Probiotics ameliorate pioglitazone-associated bone loss in diabetic rats
Open Access
- 3 September 2020
- journal article
- research article
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 12 (1) , 1-10
Abstract
Background: Pioglitazone, as a PPAR gamma agonist, is used for the management of type 2 diabetes mellitus. Nevertheless, evidence showed that the therapeutic modulation of PPAR gamma activity using pioglitazone might be linked with bone mass reduction and fracture risk in type 2 diabetes mellitus patients. The objective of the current research was to inspect the preventive role of some types of probiotic strains, including (Lactobacillus acidophilus, Lactobacillus reuteri, Lactobacillus casei, Bifidobacterium longum, and Bacillus coagulans) against pioglitazone-induced bone loss. Methods: Streptozotocin (60 mg/kg) was administered for diabetes induction. Diabetic rats were fed orally with pioglitazone (300 mg/kg) and probiotics (1 × 109 CFU/ml/day) alone and in combination for four weeks. Dual-energy X-ray absorptiometry (DXA) was used to assess BMD, BMC, and area of the femur, spine, and tibia at the end of the experiment. Serum glucose, serum calcium (Ca), alkaline phosphatase (ALP), phosphorus (P), Blood urea nitrogen (BUN), creatinine, and urine calcium were also analyzed. Results: Administration of pioglitazone and probiotics alone and, in combination, significantly reduced elevated blood glucose. Pioglitazone treatment significantly increased urinary calcium and BUN and decreased ALP and creatinine. Co-treatment of probiotics with pioglitazone significantly decreased urinary calcium, creatinine, and ALP. Pioglitazone showed detrimental effects on femur-BMD, whereas treatment with probiotics remarkably ameliorated these effects. Among the tested probiotics, Bifidobacterium longum displayed the best protective effects on pioglitazone-induced bone loss in diabetic rats. Conclusion: This study suggests probiotic supplementation in diabetic patients on pioglitazone regime could be considering as an excellent strategy to ameliorate bone loss induced by pioglitazone.Keywords
All Related Versions
Funding Information
- Shiraz University of Medical Sciences (97-01-33-18906)
This publication has 45 references indexed in Scilit:
- Probiotics as potential biotherapeutics in the management of type 2 diabetes – prospects and perspectivesDiabetes/Metabolism Research and Reviews, 2013
- Supplementation of broccoli or Bifidobacterium longum–fermented broccoli suppresses serum lipid peroxidation and osteoclast differentiation on alveolar bone surface in rats fed a high-cholesterol dietNutrition Research, 2012
- Thiazolidinediones on PPARγ: The Roles in Bone RemodelingPPAR Research, 2011
- The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseasesJournal of Advanced Pharmaceutical Technology & Research, 2011
- Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetesDiabetes, Obesity and Metabolism, 2010
- From Estrogen-Centric to Aging and Oxidative Stress: A Revised Perspective of the Pathogenesis of OsteoporosisEndocrine Reviews, 2010
- Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazoneBMC Endocrine Disorders, 2009
- Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysisCanadian Medical Association Journal, 2009
- The effect of thiazolidinediones on BMD and osteoporosisNature Clinical Practice Endocrinology & Metabolism, 2008
- TZDs and Bone: A Review of the Recent Clinical EvidencePPAR Research, 2008